Kristina Burow insider trades: Lyell Immunopharma (LYEL) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Kristina reports to the SEC
and 16 more companies
Open-market buys and sales
32 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Nov 4, 2026 | LYEL | ↑ Buy | 2,321,262 | $10.77 | $25.0M | Indirect | Nov 5, 2026 (1d) |
| Nov 2, 2026 | ASPE | ↑ Buy | 1,200,000 | $15.00 | $18.0M | Indirect | Nov 2, 2026 (0d) |
| Nov 2, 2026 | ASPE | ↑ Buy | 133,333 | $15.00 | $2.0M | Direct | Nov 2, 2026 (0d) |
| Oct 19, 2026 | CTY | ↑ Buy | 170,000 | $18.00 | $3.1M | By ARCH Venture Fund XII, L.P. | Oct 19, 2026 (0d) |
| Jul 1, 2026 | SRRK | ↓ Sell | 3,053 | $53.74 | $164K | Direct | Jul 6, 2026 (5d) |
| Jul 1, 2026 | BOLD | ↓ Sell | 16,000 | $2.49 | $40K | Indirect | Jul 6, 2026 (5d) |
| Jun 22, 2026 | KARD | ↑ Buy | 1,250,000 | $16.00 | $20.0M | By: ARCH Venture Fund XIII, L.P. | Jun 24, 2026 (2d) |
| May 4, 2026 | SPTX | ↑ Buy | 1,100,000 | $18.00 | $19.8M | By ARCH Venture Fund XII, L.P. | May 4, 2026 (0d) |
| Mar 6, 2026 | LYEL | ↑ Buy | 488,090 | $25.61 | $12.5M | Indirect | Mar 9, 2026 (3d) |
| Oct 27, 2025 | NMRA | ↑ Buy | 1,915,700 | $2.61 | $5.0M | By ARCH Venture Fund XII, L.P. | Oct 29, 2025 (2d) |
| Aug 1, 2025 | PRME | ↑ Buy | 3,030,300 | $3.30 | $10.0M | By ARCH Venture Fund XII, L.P. | Aug 1, 2025 (0d) |
| May 29, 2025 | SRRK | ↓ Sell10b5-1 | 5,400 | $29.72 | $161K | Direct | May 30, 2025 (1d) |
| Feb 3, 2025 | MTSR | ↑ Buy | 2,222,222 | $18.00 | $40.0M | Indirect | Feb 3, 2025 (0d) |
| Apr 2, 2024 | BOLD | ↑ Buy | 200,000 | $16.00 | $3.2M | Indirect | Apr 4, 2024 (2d) |
| Feb 15, 2024 | PRME | ↑ Buy | 3,200,000 | $6.25 | $20.0M | By ARCH Venture Fund XII, L.P. | Feb 20, 2024 (5d) |
| Feb 8, 2024 | SANA | ↑ Buy | 1,090,909 | $5.50 | $6.0M | Indirect | Feb 12, 2024 (4d) |
| Nov 14, 2023 | NMRA | ↑ Buy | 35,010 | $11.77 | $412K | By ARCH Venture Fund XII, L.P. | Nov 15, 2023 (1d) |
| Nov 10, 2023 | NMRA | ↑ Buy | 140,605 | $10.98 | $1.5M | By ARCH Venture Fund XII, L.P. | Nov 13, 2023 (3d) |
| Nov 7, 2023 | NMRA | ↑ Buy | 95,694 | $11.49 | $1.1M | By ARCH Venture Fund XII, L.P. | Nov 7, 2023 (0d) |
| Sep 29, 2023 | NMRA | ↑ Buy | 76,511 | $13.68 | $1.0M | By ARCH Venture Fund XII, L.P. | Sep 29, 2023 (0d) |
| Sep 27, 2023 | NMRA | ↑ Buy | 58,504 | $11.97 | $700K | By ARCH Venture Fund XII, L.P. | Sep 27, 2023 (0d) |
| Sep 25, 2023 | NMRA | ↑ Buy | 100,740 | $11.19 | $1.1M | By ARCH Venture Fund XII, L.P. | Sep 25, 2023 (0d) |
| Sep 19, 2023 | NMRA | ↑ Buy | 1,500,000 | $17.00 | $25.5M | Indirect | Sep 20, 2023 (1d) |
| Oct 24, 2022 | PRME | ↑ Buy | 400,000 | $17.00 | $6.8M | By ARCH Venture Fund X, L.P. | Oct 26, 2022 (2d) |
| Oct 24, 2022 | PRME | ↑ Buy | 400,000 | $17.00 | $6.8M | By ARCH Venture Fund X Overage, L.P. | Oct 26, 2022 (2d) |
| Jul 30, 2021 | DALS | ↑ Buy | 1,600,000 | $10.00 | $16.0M | Direct | Aug 3, 2021 (4d) |
| Sep 18, 2020 | MTCR | ↑ Buy | 230,000 | $13.00 | $3.0M | Indirect | Sep 22, 2020 (4d) |
| Oct 16, 2019 | VIR | ↑ Buy | 1,000,000 | $20.00 | $20.0M | Indirect | Oct 18, 2019 (2d) |
| Feb 22, 2019 | SNNA | ↑ Buy | 2,165,800 | $2.50 | $5.4M | Indirect | Feb 26, 2019 (4d) |
| May 29, 2014 | RCPT | ↓ Sell | 153,698 | $29.74 | $4.6M | Indirect | May 29, 2014 (0d) |
| May 14, 2014 | RCPT | ↓ Sell | 45,381 | $29.66 | $1.3M | Indirect | May 15, 2014 (1d) |
| May 14, 2013 | RCPT | ↑ Buy | 284,485 | $14.00 | $4.0M | Indirect | May 14, 2013 (0d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other LYEL insiders
Open-market trades in the last 12 months
About Kristina Burow's insider trades
Kristina Burow is a 10% owner of Lyell Immunopharma (LYEL). Since May 14, 2013, Kristina has reported 27 open-market purchases worth $278.0M and 5 sales worth $6.3M on SEC Form 4. In the last 12 months: 7 buys ($100.4M) and 2 sales ($204K).
1 sale (3% of the value sold) was made under a Rule 10b5-1 trading plan, which is set up months in advance and runs on a schedule, so it says little about how the insider sees the stock today.
Their filings also include grants and awards (38 filings), conversions (20 filings), other transactions (16 filings), shares returned to the company (4 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every LYEL insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.